Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
Ignite Proteomics’ senior clinical research scientist discusses how flaws in testing tumors may lead to some patients not receiving the correct treatment.